Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: A systematic review by Woods, TJ et al.
RESEARCH ARTICLE
Economic evaluations considering costs and
outcomes of diabetic foot ulcer infections: A
systematic review
Taylor-Jade WoodsID
1*, Fisaha TesfayID1, Peter Speck2☯, Billingsley Kaambwa1☯
1 College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 2 College of
Science and Engineering, Flinders University, Bedford Park, South Australia




Diabetic foot ulcer (DFU) is a severe complication of diabetes and particularly susceptible to
infection. DFU infection intervention efficacy is declining due to antimicrobial resistance and
a systematic review of economic evaluations considering their economic feasibility is timely
and required.
Aim
To obtain and critically appraise all available full economic evaluations jointly considering
costs and outcomes of infected DFUs.
Methods
A literature search was conducted across MedLine, CINAHL, Scopus and Cochrane Data-
base seeking evaluations published from inception to 2019 using specific key concepts. Eli-
gibility criteria were defined to guide study selection. Articles were identified by screening of
titles and abstracts, followed by a full-text review before inclusion. We identified 352 papers
that report economic analysis of the costs and outcomes of interventions aimed at diabetic
foot ulcer infections. Key characteristics of eligible economic evaluations were extracted,
and their quality assessed against the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) checklist.
Results
542 records were screened and 39 full-texts assessed for eligibility. A total of 19 papers
were included in the final analysis. All studies except one identified cost-saving or cost-effec-
tive interventions. The evaluations included in the final analysis were so heterogeneous that
comparison of them was not possible. All studies were of “excellent”, “very good” or “good”
quality when assessed against the CHEERS checklist.
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Conclusions
Consistent identification of cost-effective and cost-saving interventions may help to reduce
the DFU healthcare burden. Future research should involve clinical implementation of inter-
ventions with parallel economic evaluation rather than model-based evaluations.
Introduction
Diabetic foot ulcers (DFU) are a common and severe complication of diabetes mellitus charac-
terised by a deep tissue lesion. [1] Factors underlying the development of DFU are peripheral
sensory neuropathy, foot deformity, minor foot trauma and peripheral arterial disease. [2] It is
estimated that the annual incidence of DFU is 2–4% [3, 4] in developed countries with only
two-thirds of cases healing within 12 months. [5] A significant consequence for those DFUs
which do not heal is infection which has an incidence of 40.1%. [6] DFU infection is a well-rec-
ognised risk-factor for lower extremity amputation which occurs in 8% [5] of cases and carries
a 5-year mortality of 74%. [7]
Not only is DFU a source of significant patient suffering, it also brings significant costs to
the individual and healthcare system. The cost burden of DFU requires 6 days to 5.7 years of
patient income to cover treatment cost with variation based on setting and treatment strategy.
[8] The annual cost of DFU treatment is significantly greater than non-diabetic foot ulcer
treatment, estimated at $1.38 billion versus $0.13 billion. [9] DFU infection places an addi-
tional burden on the healthcare system. Cost per admission among patients with DFU infec-
tion versus without was significantly higher in those with infected DFU ($11,290 versus
$8,145). [9]
Cost-effective DFU interventions have been identified in previous systematic reviews of
economic evaluations, [10–13] however these reviews do not focus on those evaluations where
infection is part of the clinical presentation of the DFU or model pathway. Given the high
prevalence of infection in DFU and the accompanying economic burden, it is essential to illu-
minate potentially cost-saving or cost-effective interventions to reduce the burden of DFU
infection. We therefore seek to obtain all available economic evaluations that jointly consider
the costs and outcomes of DFU with infection considered as part of the clinical situation and
critically appraise this literature.
Methods
Search strategy
A literature search was conducted using MedLine, CINAHL, Scopus and Cochrane Databases
seeking articles published in English from inception to 2020. Terms including diabetic foot,
economic evaluation and infection were used as Medical Subject Headings (MeSH) and text-
words to capture the outcomes of interest. The MedLine search strategy, adapted for use in
other databases, is presented in Table 1. The last database search was 31 Jan 2020.
Study selection
Studies were included if:
1. they compared costs and outcomes in conjunction as part of a stand-alone economic evalu-
ation or alongside a clinical trial or other study design types such as model-based economic
evaluations,
2. the study population was exclusively 18 years and over,
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3. the study population was diabetic with an infected foot ulcer,
4. they were published in the English language in peer reviewed journals between inception
and 2020.
Studies were excluded if:
1. costs and outcomes were not considered and/or compared,
2. study population was not over the age of 18,
3. they were theory papers, letters, editorials, reviews, theses, or dissertations and studies
where full texts could not be obtained.
This systematic review was conducted according to the Preferred Reporting Items of Sys-
tematic Reviews and Meta-Analyses (PRISMA) guidelines and the checklist is provided as sup-
porting information (S1 Checklist). [14] Articles were identified by screening titles and
abstracts, followed by assessment of full-texts for eligibility.
Data extraction and quality assessment
Key characteristics of the economic evaluations were identified and extracted including study
design and perspective, study population, intervention and comparator(s), time horizon and
discount rate, methods or model used, costs included, reporting of costs, outcomes measuring
health benefit and cost-effectiveness and overall economic evaluation result.
Quality assessment of the reporting of identified studies was performed according to the
24-item Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.
[15] Two reviewers independently assessed articles against the criteria, calculating a score out
of 24. Each item was assigned one-point, partial marks were awarded if the study did not
completely fulfill the criteria, for example if perspective or discount rate choices were not
Table 1. MedLine (via Ovid) search strategy adapted for use in other databases.
Searches
1 Diabetic Foot/
2 Foot Ulcer/ and (diabetes mellitus/ or diabetes mellitus, type 1/ or diabetes mellitus, type 2/)
3 (diabet� adj3 (foot or feet or wound� or ulcer� or lesion� or lower limb� or lower extremit�)).tw,kf.
4 or/1-3
5 economics/ or "costs and cost analysis"/ or "cost allocation"/ or cost-benefit analysis/ or "cost control"/ or "cost
of illness"/ or health care costs/ or direct service costs/ or hospital costs/ or health expenditures/ or economics,
hospital/ or hospital charges/ or economics, medical/ or fees, medical/ or economics, nursing/ or economics,
pharmaceutical/
6 quality-adjusted life years/
7 (QALY or ((cost� or economic�) adj3 (minimi� or utilit� or evaluat� or review� or outcome� or analys� or
effect� or benefit))).tw,kf.
8 (cost� or economic�).ti.
9 or/5-8
10 infection/ or community-acquired infections/ or cross infection/ or opportunistic infections/ or superinfection/
or staphylococcal skin infections/ or soft tissue infections/ or suppuration/ or abscess/ or wound infection/ or
surgical wound infection/
11 Gangrene/
12 (infection� or abscess� or gangren�).tw,kf.
13 or/10-12
14 4 and 9 and 13
15 Limit 14 to English language
https://doi.org/10.1371/journal.pone.0232395.t001
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explained. Any differences in marks awarded were discussed by reviewers to reach consensus.
Calculation of a percentage score was performed. Given the absence of a largely accepted
method for quality appraisal, set categories were based on published literature. [16–19] Studies
scoring 85% or higher were of “excellent” quality, studies scoring between 70-<85% of “very
good” quality, studies scoring 55-<70% were rated to have “good” quality and studies scoring
below 55% were classified as “poor” quality.
Results
Study selection
PRISMA guidelines [14] were followed in the study selection process (Fig 1). Database
searches identified 527 studies and an additional 63 records were identified through
screening of referencing lists; 93 duplicates were removed. Titles and abstracts of 542 arti-
cles were screened for eligibility; 503 did not meet the criteria. During this stage, a second
reviewer independently assessed 20% of these articles for eligibility and interrater agree-
ment was calculated using Cohen’s kappa statistic. [20] Thirty-nine full-texts were assessed
for eligibility. Two papers did not consider DFU infection, [21, 22] three did not report
participant age, [23–25] one did not consider DFU, [26] two were review papers [27, 28]
and one was not published in a peer-reviewed journal. [29] Eleven papers did not consider
Fig 1. Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing
study selection process. DFU: diabetic foot ulcer.
https://doi.org/10.1371/journal.pone.0232395.g001
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and/or compare costs and outcomes as in a full economic evaluation. [30–40] Study eligi-
bility agreement between both reviewers was ‘almost perfect’ with a kappa statistic of 0.83.
Nineteen studies were included in the final analysis. All papers [41–59] were full economic
evaluations considering and comparing the costs and benefits of interventions against
comparators.
Economic evaluation characteristics
Study setting and cohort. Study settings were diverse and accounted for South America,
[41, 55] Australia, [42] Canada, [43] China, [59] Europe [47, 49, 51–54, 56] and North America
[44–46, 48, 50, 57, 58] (Table 2). Patients across all age groups 18 years and over were captured.
Four cohorts were derived from clinical trials [44, 50, 57, 58] and some studies focused on
moderate to severe, [48, 55–57] or non-healing [44] DFUs only. DFU infection was a part of
the clinical presentation or model pathway in all studies.
Study perspectives. The economic perspective taken by each study determines the cost
and benefits included. [17] The societal perspective was taken by Cárdenas et al. [41] and
Redekop et al. [54] The perspective of the healthcare system was taken in six studies [42, 43,
50, 55, 57, 59] and the payers perspective was taken in five [45, 46, 49, 56, 58] (Table 2). Both
the societal and payers perspectives were taken by Guo et al. [48] Perspective was not reported
in five studies, [44, 47, 51–53] however Ortegon et al. [51] discussed some results from the pol-
icy and clinical perspective.
Intervention and comparator. A multitude of interventions were used to manage DFUs,
typically antimicrobials or wound care strategies, reflecting components of the standard treat-
ment of DFUs [2, 60] (Table 2). Most economic evaluations assessed adjuncts to standard
wound care strategies. [41, 47, 54–56] Two studies assessed becaplermin gel plus good wound
care (GWC) [52, 58] and two studies assessed hyperbaric oxygen therapy (HBOT). [43, 48]
The overall wound care strategy was compared in three studies, each comparing what was
locally considered as standard versus optimal wound care. [42, 53, 59] Wound dressings were
assessed in four.
Time horizon. Time horizons should be specified and cover the provision of the interven-
tion and tracking of costs and consequences/benefits. Ideally, they should reflect actual clinical
practice. One-year [41, 45, 54, 58] and five-year time horizons were most common. [42, 44, 53,
55, 56, 59] The longest time horizon was 12-years by Chuck et al. [43] Short time horizons
were taken by Gilligan et al. [46] and Guest et al. [47] of three and four months respectively.
Two time horizons were taken in two papers, Tesar et al. [56] used 5- and 10-year time hori-
zons and Lobmann et al. [49] used 20-week and 100-week time horizons. Persson et al. time
horizon was between one and two years. [52]
Four studies did not explicitly report the time horizon. [48, 50, 51, 57] In McKinnon et al.,
[50] time horizon was ambiguous, reported as being from the beginning of study-drug com-
mencement to the completion of study-drug or secondary treatment following clinical failure.
Overall, reported time horizons ranged from 12 weeks to 12 years.
Discount rates. Discount rates allow economic evaluations to account for changes in the
value of money over time. Four studies did not report a discount rate. [43, 44, 49, 57] Three
studies used a 3% discount rate, however none of them justified this choice. [48, 51, 53] Four
studies used a 5% discount. [42, 52, 55, 59] All studies with a time horizon of one year of less
did not discount costs. [41, 45–47, 50, 54, 58]
Study designs and models used. Eleven studies were CEAs, [41–43, 45, 47, 49, 52, 54, 55,
58, 59] another five were CUAs, [44, 48, 51, 53, 56] while three studies found the interventions
were equally efficacious, therefore costs were directly compared as in a CMA. [46, 50, 57]
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Two studies did not use an economic model to simulate the impact of interventions on
DFU. [57, 58] Tice et al. performed a direct cost comparison as each intervention was assumed
to be equally efficacious. [57] Waycaster et al. used wound surface area reduction rates to pre-
dict costs associated with DFU healing. [58] Seven studies used a decision-tree analytical
model. [41, 43, 44, 47, 48, 50, 59] The Markov model was the most common choice and was
used in ten studies. [42, 45, 46, 49, 51–56]
Costs included. There was variation between cost inclusions in each study depending
on setting, perspective and interventions investigated. Some studies kept a narrow scope
of direct costs associated with the intervention [47, 56, 57] or ulcer state, [44] but most
studies had a broad scope of inclusions that captured DFU intervention, rehabilitation and
patient management. [41, 48, 49, 52–55, 58, 59] Indirect costs were only itemised in one
study. [41]
Overall economic evaluation results. All evaluations except one concluded the interven-
tion assessed was cost-effective or cost saving. This means all interventions provided more
health benefit at a lower incremental cost most of the time. All CMAs showed the intervention
achieved equal health benefit at lower costs versus the comparator.
While the evaluations are incomparable due to heterogeneous methods and analyses, the
intervention dominated the comparator in nine studies by providing greater health benefits at
lower cost. [42–45, 47, 49, 52, 54, 59] The intervention was dominated by the comparator in
one study due to the unit cost of the adjunct. [56] Six studies found the intervention to be cost-
effective [41, 48, 51, 53, 55, 58] and three found the intervention was cost saving as the health
benefits were equivalent. [46, 50, 57] Ragnarson et al. [53] found the intervention was domi-
nant or cost-effective for higher risk patients in all age groups, but was dominated by the com-
parator in the lowest risk group.
Adjuncts were dominant or cost-effective interventions in nine of ten papers. McKinnon
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versus SWC.
CEA, cost-effectiveness analysis; SWC, standard wound care; IDF, International Diabetes Federation; PEN, Peruvian Nuevos Soles; USD, United States dollar; AUD,
Australian dollar; CAD, Canadian dollar; CMA, cost-minimisation analysis; CUA, cost-utility analysis; ICER, incremental cost-effectiveness ratio; HBOT, hyperbaric
oxygen therapy; DFU, diabetic foot ulcer; PRP, platelet rich plasma; LEA, lower extremity amputation; VAC, vacuum assisted closure; ECM, extracellular matrix; HFDS,
human fibroblast-derived dermal substitute; GBP, British pound sterling; TLC-NOSF, technology lipido-colloid sucrose octasulfate or nano-oligosaccharide factor; IGC,
intensive glycemic control; GFC, good foot care; GWC, good wound care; WSA, wound surface area; rhEGF, recombinant human epidermal growth factor; SEK,
Swedish krona; OPAT, outpatient parenteral antimicrobial therapy. papers. [44–46, 49] Standard dressings were a comparator to advanced dressings or vacuum-assisted
closure (VAC) therapy [45] or technology lipido-colloid sucrose octasulfate or nano-oligosaccharide factor (TLC-NOSF) dressings. [49] Dougherty et al. [44] used a
saline dressing as a control when comparing to platelet-rich plasma (PRP) gel and Gilligan et al. [46] compared extracellular matrix (ECM) and human fibroblast-
derived dermal substitute (HFDS) dressings. McKinnon et al. [50] and Tice et al. [57] directly compared two antibiotics, one of which was considered conventional care,
but neither study used the same antibiotics.
https://doi.org/10.1371/journal.pone.0232395.t002
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saving. In the four studies which assessed dressings, three found the intervention was domi-
nant [44, 45, 49] and one found the intervention was cost-saving. [46] Three papers compared
standard wound care to optimal wound care strategies. [42, 53, 59] Cheng et al. [42] and Wu
et al. [59] found optimal wound care was dominant while Ragnarson et al. [53] found optimal
wound care was dominant or cost-effective only in higher risk groups.
Quality assessment of economic evaluations
The reporting quality of each paper was assessed against the 24-item CHEERS checklist. [15]
Studies were allocated one mark for each criterion met in full (represented by
p
), 0.5 marks if
the criterion was partially met (represented by 6¼) or if the criterion was not met, 0 marks (rep-
resented by ×) (Table 3). The total possible score was reduced by one point for all criteria that
were not applicable (N/A) to a single study. For example, studies that were not model-based
could not be assessed by criteria 15 or 16 (model justification and assumptions). Six studies
were of “excellent” quality (scoring >85%). [41, 45, 49, 55, 58, 59] Nine studies were of “very
good” quality (scoring 70-<85%) [42, 43, 46–48, 50, 52, 54, 56] and four studies were of
“good” quality (scoring 55-<70%). [44, 51, 53, 57] The best addressed criterion was findings
and limitations; conversely, the least addressed areas were study perspective, time horizons
and discount rates. Many studies failed to report these and where reported, justification of
their relevance was absent. Similarly, discussion of choice of outcomes was rarely related to
the particular health state or intervention.
Discussion
Whilst the need for effective DFU interventions increases, few have been subject to economic
evaluation. All interventions examined in these evaluations were cost-effective or cost-saving
in a clinical situation involving DFU infection. Collectively, they suggested that short- and
long-term implementation of such interventions could reduce the burden of DFU infection
on healthcare systems while providing optimal patient management. Although the evaluations
captured the standard care for DFUs and associated costs, other considerations were made on
the issue. These included assessments of antibiotic efficacy, route and setting of administration
and the overall strategies embodied in a variety of guidelines and recommendations.
Seventeen evaluations were model-based and did not implement the intervention in clinical
settings. [41–56, 59] They relied on published data and literature to build a model that simulated
the intervention and transitions between health states. Decision tree and Markov models were
used, and model justification and assumptions were generally well-reported. Although models
are widely accepted methods for informing policy-making decisions, [19] future research would
benefit from implementing the interventions in a clinical setting.
Together all evaluations assessed at least one component of the DFU management strategy,
with adjuncts assessed in most papers. Because the treatment of DFUs has multiple compo-
nents including antimicrobials and standard wound care, it was to be expected that these eco-
nomic evaluations would be too heterogeneous for comparison.
Quality assessment of studies against the CHEERS checklist [15] found all studies to be of
“excellent”, [41, 45, 49, 55, 58, 59] “very good” [42, 43, 46–48, 50, 52, 54, 56] and “good” [44,
51, 53, 57] quality, adding strength to the conclusions drawn in this review. Furthermore,
some studies included were published before the conception of the CHEERS checklist in 2013.
[15] This shows that high-quality studies with earlier publication dates conform with the
guidelines crystallised in the checklist and supports the comprehensiveness of the search
strategy.
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Table 3. Quality assessment of publications against the Consolidated Health Economic Evaluations Reporting Standards (CHEERS) checklist.
Title identified as
economic evaluation
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2015
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Cheng et al. 2017
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There are some limitations to our study. The results of this review rely exclusively upon stud-
ies published in English, which may not represent all research. Grey literature that is unpub-
lished or published but non-commercially available was not searched due to time constraints.
Full texts that could be obtained were limited to those accessible by the Flinders University
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Wu, et al 2018
p p
N/A 6¼ 6¼
p p p p
Incremental costs Sensitivity of incremental
costs or model sensitivity
analysis
Heterogeneity explanation Findings and
limitations
Funding source(s) Conflict of
interest
Total %







Cheng et al. 2017 6¼ 6¼ 6¼
p p p
19/23 82%
Chuck et al. 2008 6¼ 6¼
p p
× × 17.5/23 76%
Dougherty et al.
2008




Flack, et al 2008
p p p p
× × 20/23 87%
Incremental costs Sensitivity of incremental
costs or model sensitivity
analysis
Heterogeneity explanation Findings and
limitations
Funding source(s) Conflict of
interest
Total %
Authors, year 19 20 21 22 23 24




× × 18.5/23 80%
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Guo et al. 2003
p p p p
× × 18/24 75%
Lobmann, et al
2019












































× × 17.5/24 73%
Incremental costs Sensitivity of incremental
costs or model sensitivity
analysis
Heterogeneity explanation Findings and
limitations
Funding source(s) Conflict of
interest
Total %
Authors, year 19 20 21 22 23 24












× × 18.5/21 88%
Wu, et al 2018
p p p p p p
21.5/23 93%
p
: criteria met fully; ×: criteria not met; 6¼: criteria partially met; N/A: not applicable.
https://doi.org/10.1371/journal.pone.0232395.t003
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studies were model-based so the results relied heavily upon simulation of intervention effects
rather than clinical application.
Conclusion
In conclusion, economic evaluations have considered all aspects of DFU intervention, finding
there is potential to select more cost-saving and cost-effective alternative to reduce the burden
of DFU. Instead of model-based evaluations, future research should be directed toward actual
implementation of interventions in clinical settings with economic evaluations in parallel.
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